MLN9708, an investigational proteasome inhibitor, in patients (pts) with relapsed/refractory lymphoma: Emerging data from a phase I dose-escalation study.
Peter Martin
Honoraria - Millennium
Research Funding - Millennium
Julie E. Chang
No relevant relationships to disclose
Robert M. Rifkin
Consultant or Advisory Role - Amgen; Celgene; Millennium
Honoraria - Amgen; Celgene; Cephalon; Millennium
Ai-Min Hui
Employment or Leadership Position - Millennium
Deborah Berg
Employment or Leadership Position - Millennium
Neeraj Gupta
Employment or Leadership Position - Millennium
Guohui Liu
Employment or Leadership Position - Millennium
Alessandra Di Bacco
Employment or Leadership Position - Millennium
Sarit E. Assouline
No relevant relationships to disclose